[Form 4] EQUIFAX INC Insider Trading Activity

Rhea-AI Filing Summary

Equifax (EFX) reported an insider transaction by its EVP, Chief Technology Officer. On 10/27/2025, the officer exercised options for 4,925 shares of common stock at $175.48 per share (code M) and sold 4,925 shares at $238.94 (code S) pursuant to a Rule 10b5-1 trading plan adopted on 4/25/2025.

Following these transactions, the officer directly beneficially owned 39,364 shares. The option related to 4,925 underlying shares had an exercise price of $175.48 and an expiration of 02/21/2026, and vested in three equal annual increments beginning 2/21/2021. Holdings include accrued dividend equivalent units and shares acquired via the company’s 2020 Employee Stock Purchase Plan.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Farshchi Jamil

(Last) (First) (Middle)

1550 PEACHTREE STREET, N.W.

(Street)

ATLANTA GA 30309

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
EQUIFAX INC [ EFX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Technology Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/27/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/27/2025		M		4,925	A	$175.48	44,289(1)	D
Common Stock	10/27/2025		S(2)		4,925	D	$238.94	39,364(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option/Right to Buy	$175.48	10/27/2025		M			4,925	(3)	02/21/2026	Common Stock	4,925	$0.0000	0.0000	D

Explanation of Responses:

1. Includes accrued dividend equivalent units for dividends reinvested in corresponding restricted stock units through the Company's last dividend payment date and 372 shares of common stock purchased pursuant to the Equifax Inc. 2020 Employee Stock Purchase Plan.

2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 4/25/2025.

3. The option vested in three equal annual increments beginning 2/21/2021.

	/s/Lisa Stockard as Attorney-in-Fact	10/28/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did EFX’s CTO transact on 10/27/2025?

Exercised options for 4,925 shares at $175.48 (code M) and sold 4,925 shares at $238.94 (code S).

How many Equifax (EFX) shares does the officer hold after the transactions?

Direct beneficial ownership is 39,364 shares after the reported transactions.

Was the sale under a Rule 10b5-1 plan?

Yes. The sales were made under a Rule 10b5-1 plan adopted on 4/25/2025.

What were the option terms associated with the exercise?

The option covered 4,925 shares at an exercise price of $175.48, expiring on 02/21/2026, and vested in three equal annual increments beginning 2/21/2021.

What is the reporting person’s role at Equifax (EFX)?

The reporting person is an Officer, serving as EVP, Chief Technology Officer.

Do the reported holdings include dividend equivalents or ESPP shares?

Yes. Holdings include accrued dividend equivalent units and 372 shares purchased under the 2020 Employee Stock Purchase Plan.